Clinical Trials Browser

Resectable Hepatocellular Carcinoma × Nivolumab × Gastrointestinal × Clear all

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Phase 2 Withdrawn

Gastrointestinal

Resectable Hepatocellular Carcinoma